Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 232 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of... February 24, 2021 Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations May 17, 2021 Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival December 7, 2018 Fears breast cancer progress could stall due to COVID-19 backlog June 15, 2021 Load more HOT NEWS Addressing Cancer Pain with Complementary Methods (Part 2) ΥΓΡΗ ΒΙΟΨΙΑ: ΤΟ ΜΕΛΛΟΝ ΣΤΗ ΔΙΑΓΝΩΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ Mom Discovers She Has Breast Cancer After Weaning Twin Boys, Says... EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan
